Medulla has worked with global companies including Pfizer, Novartis, Ferring, Mylan, Braintap, Bayer, Kenvue, and more.

Drugs to treat attention deficit hyperactivity disorder were linked to a reduced risk of suicidal behavior, substance misuse and criminality in the first research of its kind.

The announcement by President Donald Trump’s administration of the results of a probe into pharmaceutical imports and new sector-specific tariffs ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

Novartis Pharmaceuticals filed a lawsuit against the State of Rhode Island seeking to block the enforcement of a new state ...

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, ...